Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited
GZPHFOTCHealthcare● Active
$2.34
+$0.00(+0.00%)
Market Cap$6.2B
P/E Ratio—
52W High$2.88
52W Low$2.14
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
GZPHF · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 27, 2026EPS Actual
$0.16
Revenue
$3.37B
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 27, 2026
After Market Close
GZPHF reports quarterly as a OTC-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 14, 2026 | — | — | — | — | — | — |
| — Q2 FY2026 | Apr 27, 2026 | — | $0.16 | — | $3.37B | — | — |
| ▼ Q1 FY2026 | Mar 20, 2026 | $0.06 | -$0.03 | -145.4% | $2.29B | $2.26B | +1.5% |
| ▲ Q4 FY2025 | Oct 28, 2025 | $0.06 | $0.07 | +13.5% | $2.78B | — | — |
| ▼ Q2 FY2025 | Jun 30, 2025 | $0.06 | $0.06 | -5.1% | $2.70B | — | — |
| ▲ Q2 FY2025 | Apr 29, 2025 | $0.08 | $0.15 | +103.0% | $3.09B | — | — |
| — Q4 FY2024 | Dec 31, 2024 | — | -$0.03 | — | $2.18B | — | — |
| ▼ Q4 FY2024 | Oct 25, 2024 | $0.06 | $0.05 | -16.7% | $2.57B | $2.61B | -1.8% |
Q3 FY2026
Aug 14, 2026
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 27, 2026
EPS Actual
$0.16
EPS Est.
—
EPS Surpr.
—
Revenue
$3.37B
Q1 FY2026
Mar 20, 2026Miss
EPS Actual
-$0.03
EPS Est.
$0.06
EPS Surpr.
-145.4%
Revenue
$2.29B
Q4 FY2025
Oct 28, 2025Beat
EPS Actual
$0.07
EPS Est.
$0.06
EPS Surpr.
+13.5%
Revenue
$2.78B
Q2 FY2025
Jun 30, 2025Miss
EPS Actual
$0.06
EPS Est.
$0.06
EPS Surpr.
-5.1%
Revenue
$2.70B
Q2 FY2025
Apr 29, 2025Beat
EPS Actual
$0.15
EPS Est.
$0.08
EPS Surpr.
+103.0%
Revenue
$3.09B
Q4 FY2024
Dec 31, 2024
EPS Actual
-$0.03
EPS Est.
—
EPS Surpr.
—
Revenue
$2.18B
Q4 FY2024
Oct 25, 2024Miss
EPS Actual
$0.05
EPS Est.
$0.06
EPS Surpr.
-16.7%
Revenue
$2.57B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $0.44 | $0.44 | $0.44 | 1 |
| Q3 FY2025 | $0.43 | $0.43 | $0.43 | 1 |
| Q2 FY2025 | $0.45 | $0.45 | $0.45 | 1 |
| Q1 FY2025 | $0.55 | $0.55 | $0.55 | 1 |
| Q4 FY2024 | $0.30 | $0.30 | $0.30 | 1 |
| Q4 FY2022 | $0.10 | $0.10 | $0.10 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2025 | $15.8B | $15.8B | $15.8B | 1 |
| Q3 FY2025 | $19.8B | $19.8B | $19.8B | 1 |
| Q2 FY2025 | $19.4B | $19.4B | $19.4B | 1 |
| Q1 FY2025 | $24.8B | $24.8B | $24.8B | 1 |
| Q4 FY2024 | $18.6B | $18.6B | $18.6B | 1 |
| Q4 FY2022 | $13.3B | $13.3B | $13.3B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q2 FY2026 | Apr 27, 2026 | — | $2.34 | $2.34 | +0.00% |
| ▼ Q1 FY2026 | Mar 20, 2026 | -145.4% | $2.34 | $2.34 | +0.00% |
| ▲ Q4 FY2025 | Oct 28, 2025 | +13.5% | $2.34 | $2.34 | +0.00% |
| ▼ Q2 FY2025 | Jun 30, 2025 | -5.1% | $2.23 | $2.23 | +0.00% |
| ▲ Q2 FY2025 | Apr 29, 2025 | +103.0% | $2.37 | $2.25 | -5.06% |
| — Q4 FY2024 | Dec 31, 2024 | — | $2.88 | $2.88 | +0.00% |
| ▼ Q4 FY2024 | Oct 25, 2024 | -16.7% | $2.88 | $2.88 | +0.00% |
| — Q3 FY2024 | Aug 30, 2024 | — | $2.88 | $2.88 | +0.00% |
Q2 FY2026+0.00%
Report Date
Apr 27, 2026
EPS Beat/Miss
—
Price Before
$2.34
Price After
$2.34
Q1 FY2026+0.00%
Report Date
Mar 20, 2026
EPS Beat/Miss
-145.4%
Price Before
$2.34
Price After
$2.34
Q4 FY2025+0.00%
Report Date
Oct 28, 2025
EPS Beat/Miss
+13.5%
Price Before
$2.34
Price After
$2.34
Q2 FY2025+0.00%
Report Date
Jun 30, 2025
EPS Beat/Miss
-5.1%
Price Before
$2.23
Price After
$2.23
Q2 FY2025-5.06%
Report Date
Apr 29, 2025
EPS Beat/Miss
+103.0%
Price Before
$2.37
Price After
$2.25
Q4 FY2024+0.00%
Report Date
Dec 31, 2024
EPS Beat/Miss
—
Price Before
$2.88
Price After
$2.88
Q4 FY2024+0.00%
Report Date
Oct 25, 2024
EPS Beat/Miss
-16.7%
Price Before
$2.88
Price After
$2.88
Q3 FY2024+0.00%
Report Date
Aug 30, 2024
EPS Beat/Miss
—
Price Before
$2.88
Price After
$2.88
Avg Beat Reaction-2.53%
Avg Miss Reaction+0.00%
Beat Rate2 / 8 quarters
Largest Move-5.06% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: GZPHF ends December
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GZPHF) most recently reported earnings on April 27, 2026 for Q2 FY2026, posting EPS of $0.16 (in line with the analyst consensus of —). The next GZPHF earnings date is expected around September 1, 2026.
Each quarter, investors track GZPHF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. GZPHF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
GZPHF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
GZPHF earnings · 4 questionsGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited's next earnings report is expected around September 1, 2026. GZPHF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; GZPHF historically reports after market close (AMC).
GZPHF earnings datewhen is GZPHF earningsGZPHF next earnings datewhen does GZPHF report earningsGZPHF earnings calendar
▸ Source: FMP · Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited SEC filings · US GAAP · Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026